<DOC>
	<DOCNO>NCT02728388</DOCNO>
	<brief_summary>The investigator wish determine time disease progression benign neurofibromas treat Levulan Kerastick topical photosensitizer red light photodynamic therapy ( PDT ) patient neurofibromatosis type 1 ( NF1 ) . The investigator also wish measure tumor size control treatment tumor order gain insight tumor growth rate .</brief_summary>
	<brief_title>Photodynamic Therapy Benign Dermal Neurofibromas</brief_title>
	<detailed_description>Neurofibromas contain large quantity fibrous matter , anticipate significant reduction tumor size achieve large , long establish , tumor . Cutaneous neurofibroma , usually become apparent puberty , continue increase size number throughout adulthood . The psychosocial burden disfigure tumor significant , targeted age group ( 14-30 ) life period associate acceleration tumor growth . It reason investigator hope affect growth rate less establish tumor , order prevent lessen burden patient progress adulthood . Therefore , investigator wish determine time disease progression ( defined 50 % growth size baseline ) benign neurofibromas treat PDT patient neurofibromatosis type 1 ( NF1 ) subject age 14-30 . The treatment consist choose several neurofibroma similar size , apply topical drug call Levulan , topical application alone ( placebo ) . After 1 day , neurofibromas illuminate red light ( Levulan placebo ) . The Levulan know photosensitizer , activate red light potentially kill tumor cell . Every 4 month , three year , tumor measure see grow slowly one placebo application alone .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Nerve Sheath Neoplasms</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>1 . Patient 14 year old . 2 . Diagnosed NF1 , determine American Academy Neurology Guidelines ( see Diagnosis section ) . 3 . Tumor Location : cutaneous , trunk , limb . 4 . Tumor Type : superficial dermal neurofibroma â‰¤4mm deep . 5 . Patient provide write informed consent . 6 . Patient willing comply study followup requirement . 7 . Absence malignancy . 1 . Life expectancy le 3 year . 2 . Pregnancy . 3 . Cutaneous photosensitivity wavelength use active PDT . 4 . A diagnosis porphyria . 5 . Allergy aminolevulinic acid topical solution vehicle component . 6 . Previous chemotherapy within 6 week propose PDT . 7 . Other concurrent tumor therapy .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>NF1</keyword>
	<keyword>Neurofibroma</keyword>
	<keyword>Neurofibromatosis Type 1</keyword>
</DOC>